---
provider: openai
model: o3-deep-research-2025-06-26
cached: false
start_time: '2025-11-19T15:04:20.255889'
end_time: '2025-11-19T15:11:42.310553'
duration_seconds: 442.05
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    top_p: 1.0
citation_count: 83
---

## Question

Here is a pathway that describes how a drug might affect a disease:

**Pathway:** SmallMolecule: Sorafenib | treats_or_applied_or_studied_to_treat | Disease: basal cell carcinoma | treats_or_applied_or_studied_to_treat | SmallMolecule: Cetuximab | treats_or_applied_or_studied_to_treat | Disease: liver carcinoma

**Drug:** Sorafenib
**Disease:** liver carcinoma

What is the biological plausibility of this drug-disease relationship?

Score on a scale of:
- 1 = Totally implausible (doesn't make sense biologically and no support in literature)
- 2 = Seems implausible (no support in literature)
- 3 = Seems plausible (no support in literature)
- 4 = Very plausible (some support in literature)
- 5 = Totally plausible (mechanism already described)

Consider:
- Has this exact mechanism been described in the literature?
- Do all, most, or some of the steps in the pathway have support in the literature?
- Do all, most, or some of the steps seem biologically plausible even without direct literature support?


## Output

# Biological Plausibility of Sorafenib for Liver Carcinoma (HCC)

## Key Concepts and Definitions  
**Sorafenib:** Sorafenib is an oral small-molecule multikinase inhibitor initially approved for advanced renal cell carcinoma and later for unresectable hepatocellular carcinoma (HCC) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20720388/#:~:text=The%20multikinase%20inhibitor%20sorafenib%20is,BCC%29%20while)). It targets multiple signaling pathways: notably, it inhibits serine/threonine kinases in the Ras/Raf/MEK/ERK pathway (including Raf-1 and B-Raf) and receptor tyrosine kinases linked to angiogenesis such as VEGF receptors and PDGFR-β ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=Sorafenib%20is%20an%20oral%20multi,10)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC)). By blocking these pathways, Sorafenib reduces tumor cell proliferation, induces apoptosis, and inhibits tumor angiogenesis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=Primary%20liver%20cancer%20is%20a,such%20as%20epigenetic%20regulation)). In clinical practice, Sorafenib was the first systemic drug to show a survival benefit in HCC, marking a breakthrough in 2007 when no effective systemic therapy for HCC existed ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no)).  

**Basal Cell Carcinoma (BCC):** BCC is the most common form of skin cancer, arising from basal epidermal cells. It is typically a locally invasive skin tumor with rare metastasis, driven primarily by aberrations in the Hedgehog signaling pathway. Most BCCs are effectively cured by surgical excision, but advanced or unresectable cases may require systemic therapy. **EGFR in BCC:** Many BCC tumors express the epidermal growth factor receptor (EGFR) – studies have shown EGFR is overexpressed in ~57% of BCCs (and ~80% of cutaneous squamous cell carcinomas) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=and%20reduced%20apoptosis%20,the%20malignant%20transformation%20of%20cells)). While Hedgehog pathway activation is the key driver in BCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=aberration%20in%20EGFR%20pathways%20is,the%20effectiveness%20of%20cetuximab%20in)), EGFR signaling can act synergistically with Hedgehog signaling in these cancers ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=malignancies,cetuximab%20in%20patients%20with%20BCC)). This provides a rationale for targeting EGFR in advanced BCC, even though EGFR is not the primary oncogenic pathway. The **standard systemic treatments for advanced BCC** now are Hedgehog pathway inhibitors (e.g. vismodegib), reflecting the central role of that pathway ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=aberration%20in%20EGFR%20pathways%20is,the%20effectiveness%20of%20cetuximab%20in)). Sorafenib is **not a standard therapy for BCC** and is not known to inhibit the Hedgehog pathway. In fact, there is *no literature support* for using Sorafenib to treat BCC – if anything, case reports note Sorafenib therapy has been associated with *new* cutaneous malignancies (actinic keratoses, squamous cell carcinomas, and even BCCs) as a paradoxical side effect ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20720388/#:~:text=The%20multikinase%20inhibitor%20sorafenib%20is,BCC%29%20while)). Thus, the link “Sorafenib treats BCC” in the proposed pathway has **no positive support** (it is biologically questionable, since Sorafenib’s targets don’t address BCC’s main driver, and reports suggest Sorafenib can induce skin tumors rather than cure them). 

**Cetuximab:** Cetuximab is a chimeric monoclonal antibody that targets EGFR. By binding EGFR on cell surfaces, Cetuximab prevents receptor activation and downstream signaling through the Ras/Raf/ERK pathway ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Cetuximab%20is%20a%20chimeric%20human%2Fmurine,There%20are%20reported%20cases)). It is an established therapy for EGFR-expressing cancers such as metastatic colorectal cancer (with wild-type KRAS) and squamous cell carcinoma of the head and neck. **In skin cancers:** Cetuximab has been explored as a treatment for advanced non-melanoma skin cancers, given the high EGFR expression in some of these tumors. A 2012 clinical study (Kalapurakal *et al.*, *J Cancer* 2012) evaluated Cetuximab in 8 patients with refractory cutaneous carcinomas (4 BCC, 4 SCC) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Platinum,which%20were%20treated%20with%20cetuximab)). Notably, **3 of 4 basal cell carcinoma patients achieved remission** (complete or partial) on Cetuximab therapy ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Results%3A%20Three%20of%20the%20four,and%20dose%20reduction%20in%20another)). These responses suggest that blocking EGFR can slow or regress advanced BCC in some cases – likely because EGFR signaling contributes to the tumor’s growth alongside Hedgehog pathway activity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=aberration%20in%20EGFR%20pathways%20is,cetuximab%20in%20patients%20with%20BCC)). Cetuximab was reasonably well tolerated in that setting, with acneiform rash as the main side effect ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=University%20School%20of%20Medicine%20%28SIU,Medical%20Oncology%20clinic)). Although Cetuximab is not a first-line medication for BCC, this evidence provides **some support** that the step “Disease: basal cell carcinoma –> Cetuximab (treatment)” is biologically plausible and has been observed in the literature (at least in small studies). 

**Liver Carcinoma (Hepatocellular Carcinoma, HCC):** HCC is the dominant form of primary liver cancer, often arising in the context of chronic liver disease or cirrhosis (e.g. due to hepatitis B/C infection, alcohol abuse, or fatty liver disease). HCC is typically highly vascular and prone to rapid growth and metastasis in advanced stages ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC)). Prior to 2007, no systemic chemotherapy had improved survival in advanced HCC – a notoriously treatment-refractory tumor ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC)). The biology of HCC involves multiple dysregulated pathways: angiogenesis (VEGF signaling), growth signaling (e.g. RAF/MEK/ERK, PI3K/AKT), immune evasion, etc. EGFR is **often expressed** in HCC tumors (many HCCs show EGFR and ligand overexpression) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Background%3A%20Epidermal%20growth%20factor%20receptor,in%20patients%20with%20advanced%20HCC)), which made EGFR a potential therapeutic target in research. However, HCC’s driver pathways are heterogeneous; in clinical trials, single-agent EGFR inhibition proved insufficient (more on this below). 

## Pathway Analysis: Sorafenib → BCC → Cetuximab → HCC  
The given pathway connects **Sorafenib** to **liver carcinoma (HCC)** through two intermediates: basal cell carcinoma and Cetuximab. Interpreting this chain: it suggests a hypothetical mechanism where Sorafenib treats or is studied in BCC, BCC in turn is treated or linked to Cetuximab, and Cetuximab is used to treat HCC. We will examine each step for biological plausibility and literature support:

- **Step 1: Sorafenib applied to treat basal cell carcinoma.** This step is biologically **unlikely** and not supported by existing research. Sorafenib’s mode of action (RAF kinase and VEGF inhibition) is misaligned with BCC’s primary oncogenic driver (Hedgehog pathway activation). There are *no clinical trials or case reports* demonstrating Sorafenib’s efficacy in BCC. On the contrary, Sorafenib has well-documented cutaneous side effects and has been associated with the *appearance* of new keratinocyte carcinomas (actinic keratoses, squamous cell carcinomas, and even BCC) during therapy ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20720388/#:~:text=The%20multikinase%20inhibitor%20sorafenib%20is,BCC%29%20while)). This paradoxical effect is thought to result from complex RAF pathway feedback activation in the skin. The literature thus provides **no positive evidence** that Sorafenib can treat BCC; biologically, this step “doesn’t make sense” given the discordant mechanisms. We can consider this step **implausible**. (Plausibility score for this step alone: *1*, totally implausible).  

- **Step 2: Basal cell carcinoma treated with Cetuximab.** This connection has **some support** in medical literature. As noted, advanced BCC lesions often express EGFR and can depend on EGFR signaling to some extent ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=and%20reduced%20apoptosis%20,the%20effectiveness%20of%20cetuximab%20in)). Cetuximab, an EGFR-blocking antibody, has been tried in refractory BCC patients. In a small 2012 series, four patients with aggressive, unresectable BCC were treated with Cetuximab; **50% achieved complete remission and 50% partial remission**, though most responded tumors eventually recurred when therapy was paused ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Platinum,which%20were%20treated%20with%20cetuximab)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Among%20the%20four%20patients%20with,disease%20remission%20had%20been%20attained)). Continuous or maintenance Cetuximab was needed for sustained control in some cases ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Among%20the%20four%20patients%20with,disease%20remission%20had%20been%20attained)). These results suggest that EGFR contributes to BCC progression and that Cetuximab can produce tumor regression in at least a subset of cases. The biological rationale is that EGFR signaling may synergize with Hedgehog pathway signaling in BCC cells, so inhibiting EGFR disrupts that synergy and slows tumor growth ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=aberration%20in%20EGFR%20pathways%20is,cetuximab%20in%20patients%20with%20BCC)). Thus, “BCC –> Cetuximab” is **biologically plausible and somewhat supported** (Cetuximab efficacy in BCC has been reported, although this is not a standard or widely used treatment). We would rate this step’s plausibility as moderate to high (score *4*: very plausible, with some literature support).  

- **Step 3: Cetuximab applied to treat hepatocellular carcinoma.** This link was **hypothesized and tested in the literature, but found to be ineffective**. Because many HCC tumors overexpress EGFR, researchers in the 2000s reasoned that an EGFR inhibitor like Cetuximab might benefit HCC patients ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Background%3A%20Epidermal%20growth%20factor%20receptor,in%20patients%20with%20advanced%20HCC)). A Phase II clinical trial in 2007 evaluated Cetuximab monotherapy in 30 patients with advanced HCC ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Background%3A%20Epidermal%20growth%20factor%20receptor,in%20patients%20with%20advanced%20HCC)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Results%3A%20Thirty%20patients%20were%20enrolled,3)). The outcome was disappointing: **zero objective responses** were observed (none of the tumors shrank), and only 5 patients achieved temporary stable disease ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Results%3A%20Thirty%20patients%20were%20enrolled,3)). Median progression-free survival was only ~1.4 months, and median overall survival was 9.6 months – similar to typical outcomes in that advanced setting without effective therapy ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Results%3A%20Thirty%20patients%20were%20enrolled,3)). The authors concluded that Cetuximab, while safe, showed *no meaningful antitumor activity* in HCC ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Conclusions%3A%20Although%20cetuximab%20could%20be,mild%20to%20moderate%20hepatic%20dysfunction)). Biologically, this implies that **blocking EGFR alone is not sufficient** to alter the course of HCC for most patients. HCC might rely on other growth pathways and is a complex tumor with a highly vascular microenvironment; simply inhibiting EGFR did not translate into clinical benefit. Therefore, the step “Cetuximab treats HCC” is **not supported by evidence of efficacy** (it was tested and essentially failed). We can still call it *plausible in theory* (since EGFR is present in HCC, there was a rationale to try), but given the trial results, it turned out to be ineffective. This would merit a low plausibility score, perhaps *2–3* (some biological rationale, but essentially **no supportive outcomes** in the literature).

Considering the entire chained pathway **Sorafenib → BCC → Cetuximab → HCC**: All intermediate steps would need to hold true for this exact mechanism to be valid. In summary, **Step 1 is implausible**, Step 2 has some proof-of-concept support, and **Step 3, while attempted, did not yield positive results**. The exact multi-step mechanism implied (where Sorafenib’s benefit in HCC would depend on it treating BCC or an EGFR-related cascade) **has not been described in the literature**. There is no publication linking Sorafenib’s effect on HCC through a basal-cell-carcinoma/EGFR pathway. Thus, the specific *pathway as written* is not a recognized or necessary mechanism. However, there may be an indirect conceptual link: Sorafenib targets the RAF/MEK/ERK pathway, which is downstream of EGFR. If we interpret the chain abstractly, it hints that **Sorafenib and Cetuximab share a related pathway (EGFR→RAS/RAF)**, and both were explored in overlapping disease contexts. In BCC, EGFR blockade (Cetuximab) can slow tumor growth, and Sorafenib might theoretically also dampen downstream signaling (RAF) from EGFR – but again, Sorafenib is not reported for BCC. In HCC, Sorafenib achieved success by targeting angiogenesis and RAF signaling, whereas EGFR blockade did not help, suggesting HCC relies more on other pathways (VEGF-mediated angiogenesis, for example, which Sorafenib inhibits ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC))). 

## Sorafenib and Liver Carcinoma: Mechanism and Evidence  
Focusing directly on the **Drug–Disease pair of interest: Sorafenib and liver carcinoma (HCC)**, the relationship is **well-established** in oncology. Sorafenib’s ability to treat HCC has strong biological and clinical backing:

- **Mechanism in HCC:** HCC tumors are highly vascular; they often over-produce vascular endothelial growth factor (VEGF) and other pro-angiogenic signals to sustain their blood supply ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC)). Sorafenib inhibits the VEGFR-2 and -3 on endothelial cells, starving the tumor of new blood vessels. It also inhibits PDGFR-β and c-KIT, affecting tumor stroma and other growth factors ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=Raf%20kinases%20and%20vascular%20endothelial,a%20RCT%20with%20a%20similar)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=match%20at%20L682%20pathways,many%20trials%20that%20failed%20to)). Importantly, Sorafenib blocks the Raf kinase (among others) in tumor cells, thereby dampening the Raf/MEK/ERK pathway that many HCCs use for proliferation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=Raf%20kinases%20and%20vascular%20endothelial,a%20RCT%20with%20a%20similar)). By hitting both **angiogenesis** and **cell proliferation** pathways, Sorafenib can slow tumor growth and spread. This multitarget mechanism is biologically **plausible and relevant** for HCC, as evidenced by preclinical models and biomarker studies ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=angiogenesis%20effects%20in%20cancers%2C%20including,diarrhea%2C%20fatigue%2C%20and%20skin%20toxicity)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=signal%20transduction%20pathways%20control%20the,7%3B%20Chang%20et%20al%202007)). In essence, Sorafenib attacks two hallmarks of liver cancer: unchecked cell division (through Raf/ERK pathway inhibition) and abnormal blood vessel formation (through VEGFR inhibition).

- **Clinical evidence:** The therapeutic effect of Sorafenib in HCC has been demonstrated in large randomized trials. The landmark **SHARP trial** (Sorafenib HCC Assessment Randomized Protocol), published in 2008 (Llovet et al., *NEJM*), was a Phase III study in patients with advanced HCC. It showed a significant survival benefit: **median overall survival was 10.7 months with Sorafenib vs 7.9 months with placebo** ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/19496710/#:~:text=characteristics,prolonging%20median%20survival%20and%20time)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no)). This roughly 3-month improvement (hazard ratio ~0.69) established Sorafenib as the first effective systemic therapy for HCC ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/19496710/#:~:text=characteristics,prolonging%20median%20survival%20and%20time)). Tumor progression was also delayed (median time to progression 5.5 vs 2.8 months on placebo) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/19496710/#:~:text=characteristics,prolonging%20median%20survival%20and%20time)). A concurrent Phase III in the Asia-Pacific region confirmed similar results (hazard ratio ~0.68 for overall survival) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=response%20with%20sorafenib,68%20and)). Though Sorafenib’s tumor **response rate** was low (few outright tumor shrinkages), it achieved disease stabilization in a significant fraction of patients, translating into prolonged survival ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=difference%20in%20sorafenib%20and%20placebo%2C,ORR%29%20were%20disappointing)). These results have been widely cited and are the basis for Sorafenib’s FDA approval in HCC (gained in late 2007). In short, the **literature unequivocally supports Sorafenib’s efficacy in HCC**, and its mechanism of action in this disease is well-described ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=receptor%20tyrosine%20kinases%20associated%20with,agent%20for%20systemic%20chemotherapy%20in)). This places the Sorafenib–HCC relationship at the high end of the plausibility spectrum (“mechanism already described in literature”).

- **Current clinical application:** From 2007 until the late 2010s, Sorafenib was the **standard first-line therapy** for advanced HCC worldwide ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=match%20at%20L727%20In%20the,MKI%2C%20to%20the%20treatment%20arsenal)). It remained the only systemic option proven to extend survival for about a decade, as numerous other drugs failed to outperform it in trials ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=match%20at%20L727%20In%20the,MKI%2C%20to%20the%20treatment%20arsenal)). In recent years, the landscape has evolved with the advent of newer treatments (e.g. the multikinase inhibitor lenvatinib, and immune checkpoint inhibitor combinations). In 2018, lenvatinib was shown to be non-inferior to Sorafenib, offering an alternative first-line TKI ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=In%20the%20ten%20years%20following,MKI%2C%20to%20the%20treatment%20arsenal)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=superiority,in%20the%20lenvatinib%20arm%20showed)). More dramatically, in 2020, a combination of atezolizumab (an anti–PD-L1 immunotherapy) plus bevacizumab (an anti-VEGF antibody) demonstrated superior survival to Sorafenib in a Phase III trial (IMbrave150), shifting the preferred first-line therapy toward immunotherapy for many patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=bevacizumab%20vs.%20sorafenib%20%20,19.2%20vs.%2013.4)). For example, median overall survival with atezolizumab+bevacizumab was ~19.2 months vs 13.4 months with Sorafenib in that study ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=bevacizumab%20vs.%20sorafenib%20%20,19.2%20vs.%2013.4)). **Nonetheless, Sorafenib remains biologically and clinically relevant:** it is still approved and used, especially in settings where immunotherapy is contraindicated or unavailable. Expert guidelines in 2023 acknowledge that **if a patient with advanced HCC cannot receive first-line immunotherapy, Sorafenib (or lenvatinib) should be considered as an effective first-line option** ([link.springer.com](https://link.springer.com/article/10.1007/s12094-024-03568-4#:~:text=Some%20patients%20with%20advanced%20HCC,could%20still%20be%20considered)). Sorafenib is also used as a control or backbone in many trials, and sometimes in combination strategies. Ongoing research in 2023-2024 is intensely focused on overcoming Sorafenib resistance mechanisms in HCC, such as tumor microenvironment factors, cancer cell plasticity, and alternative signaling activation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=promote%20cell%20apoptosis%2C%20and%20inhibit,as%20targeting%20epigenetic%20pathways%20or)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=,future%20research%20and%20clinical%20application)). This research underscores that while Sorafenib’s *initial* anti-tumor effect is established, tumors often adapt, and scientists are devising combination therapies (adding other targeted drugs, chemotherapies, or immunotherapies) to improve outcomes beyond Sorafenib alone ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=urgent%20problem%20to%20be%20solved,provide%20suggestions%20for%20future%20in)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=programmed%20cell%20death%2C%20metabolic%20reprogramming%2C,depth%20research%20and%20clinical%20applications)). The continuous study of Sorafenib in recent literature (including 2023/24) reflects its importance as a therapeutic cornerstone and the need to enhance its efficacy or replace it in the evolving treatment paradigm.

- **Expert opinions:** Oncologists and liver cancer experts consider Sorafenib a paradigm-changing drug. As one 2024 multidisciplinary review stated, *“No effective systemic treatments were available until sorafenib… Sorafenib, a tyrosine kinase inhibitor, was shown to be superior to placebo. HCC is a highly vascular tumor… Sorafenib inhibits VEGF, PDGFR, Raf, Ras, MEK, ERK, c-KIT, and RET”*, attacking critical pathways in HCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC)). This encapsulates the expert understanding of why Sorafenib works in HCC. The drug is generally well tolerated; common side effects include hand–foot skin reaction, diarrhea, hypertension, and fatigue, manageable in most patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=Sorafenib%20was%20shown%20to%20have,HFS%29%2C%20alopecia%2C%20and%20anorexia)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=was%20different,significant%20hypertension%2C%20proteinuria%2C%20and%20hypothyroidism)). In practice, Sorafenib’s modest survival benefit is viewed as clinically meaningful given how aggressive advanced HCC is, but also as a baseline to improve upon. The emergence of better therapies has slightly relegated Sorafenib, yet it remains a **validated, mechanism-driven treatment** for liver carcinoma.

## Biological Plausibility Score  
Bringing the analysis together: **How biologically plausible is the relationship between Sorafenib (drug) and liver carcinoma (disease)?** On the 1–5 plausibility scale:

- **Score: 5 – Totally plausible.** This score corresponds to “mechanism already described.” In the case of Sorafenib for HCC, the mechanism is not only described but has been empirically confirmed in clinical trials. Sorafenib’s target pathways (RAF kinase and VEGF signaling) are directly relevant to HCC biology, providing a strong mechanistic rationale ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC)). Moreover, multiple studies and over a decade of clinical experience document that Sorafenib can slow HCC progression and extend patient survival ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=response%20with%20sorafenib,68%20and)). This goes beyond theoretical plausibility – it’s an **established therapeutic relationship**. 

**Justification:** All lines of evidence converge to support a **high plausibility** for Sorafenib treating liver carcinoma. The exact multi-step pathway given (via BCC and Cetuximab) is not actually needed to explain Sorafenib’s effect on HCC – Sorafenib works through its own multi-kinase inhibition mechanism in the liver. Indeed, **each step of the given pathway, taken individually, ranges from unsupported to partially supported, but the final connection (Sorafenib–HCC)** is firmly supported:

- Literature does **not** describe the full Sorafenib→BCC→Cetuximab→HCC chain as a mechanism, so in that literal sense the pathway is speculative. However, this does not detract from the direct drug-disease link already proven between Sorafenib and HCC.  
- Most of the intermediate steps are at least **biologically plausible** (Cetuximab can treat BCC; EGFR is present in HCC even if Cetuximab didn’t succeed clinically), but one step (Sorafenib treating BCC) is **implausible**. Given the lack of need for that step, one could bypass it entirely. Sorafenib does not require an effect on BCC or EGFR to impact HCC – it targets HCC via other pathways. In fact, Sorafenib’s efficacy in HCC might explain why Cetuximab alone wasn’t enough: Sorafenib hits VEGF-driven angiogenesis, which is crucial in HCC, whereas Cetuximab only hit EGFR and showed no benefit ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Conclusions%3A%20Although%20cetuximab%20could%20be,mild%20to%20moderate%20hepatic%20dysfunction)). This highlights that **Sorafenib’s known mechanism (anti-angiogenic and anti-proliferative) is the relevant one for HCC**, and that mechanism has been documented extensively ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=angiogenesis%20effects%20in%20cancers%2C%20including,diarrhea%2C%20fatigue%2C%20and%20skin%20toxicity)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=match%20at%20L682%20pathways,many%20trials%20that%20failed%20to)). 

- **Support in literature:** All or most steps of Sorafenib’s action in HCC have support. Sorafenib’s binding targets and effects on tumor biology have been mapped in preclinical studies ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=signal%20transduction%20pathways%20control%20the,7%3B%20Chang%20et%20al%202007)). The improvement in survival in patients (clinical evidence) is recorded in high-quality trials ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no)). Even resistance mechanisms are being published and addressed, underscoring that the drug’s interaction with HCC is a real, studied phenomenon ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=urgent%20problem%20to%20be%20solved,provide%20suggestions%20for%20future%20in)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=Sorafenib%20is%20an%20oral%20multi,10)). 

- **Biological sense:** There is a clear biological explanation for why Sorafenib works in HCC. HCC needs blood supply; Sorafenib cuts it off. HCC often signals through Raf/ERK; Sorafenib interrupts that signaling. These are fundamental tumor processes that Sorafenib disrupts, aligning with our understanding of HCC pathophysiology. By contrast, if something were “totally implausible,” we’d expect no sensible mechanism and no evidence – which is not the case here.

In conclusion, **Sorafenib treating liver carcinoma is biologically and clinically **“totally plausible” (Score = 5)**. The drug-disease relationship is not only plausible but realized in practice, with a described mechanism of action and substantial literature support. While the specific intermediary path (involving basal cell carcinoma and Cetuximab) is an unusual and not validated route, the core concept that Sorafenib can benefit liver cancer patients is firmly grounded in scientific evidence. 

**References:**

- Llovet JM *et al.* (2008). *NEJM* – Sorafenib in advanced hepatocellular carcinoma (SHARP trial) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=response%20with%20sorafenib,68%20and)).  
- Cheng AL *et al.* (2009). *Lancet Oncol* – Sorafenib in Asian-Pacific patients with HCC (confirmatory trial) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=response%20with%20sorafenib,68%20and)).  
- Furuse J. (2008). *Biologics* – Review of Sorafenib for unresectable HCC (mechanisms and trials) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=Raf%20kinases%20and%20vascular%20endothelial,a%20RCT%20with%20a%20similar)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=receptor%20tyrosine%20kinases%20associated%20with,agent%20for%20systemic%20chemotherapy%20in)).  
- Kalapurakal SJ *et al.* (2012). *J Cancer* – Cetuximab in refractory basal cell and squamous cell skin cancers ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Platinum,which%20were%20treated%20with%20cetuximab)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Results%3A%20Three%20of%20the%20four,and%20dose%20reduction%20in%20another)).  
- Philip PA *et al.* (2007). *Cancer* – Phase II trial of Cetuximab in advanced HCC (no objective responses) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Results%3A%20Thirty%20patients%20were%20enrolled,3)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Conclusions%3A%20Although%20cetuximab%20could%20be,mild%20to%20moderate%20hepatic%20dysfunction)).  
- Degen A *et al.* (2010). *Dermatology* – Reports of basal cell carcinoma arising during Sorafenib therapy ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20720388/#:~:text=The%20multikinase%20inhibitor%20sorafenib%20is,BCC%29%20while)).  
- Huang C *et al.* (2025). *Int J Surg* – Review of Sorafenib resistance mechanisms in HCC (summarizing 2020s research) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=promote%20cell%20apoptosis%2C%20and%20inhibit,as%20targeting%20epigenetic%20pathways%20or)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=Sorafenib%20is%20an%20oral%20multi,10)).  
- SEOM Clinical Guidelines (2023) – Hepatocarcinoma management, noting Sorafenib still viable if immunotherapy unsuitable ([link.springer.com](https://link.springer.com/article/10.1007/s12094-024-03568-4#:~:text=Some%20patients%20with%20advanced%20HCC,could%20still%20be%20considered)).  



## Citations

1. AnnotationURLCitation(end_index=424, start_index=284, title='Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20720388/#:~:text=The%20multikinase%20inhibitor%20sorafenib%20is,BCC%29%20while')
2. AnnotationURLCitation(end_index=781, start_index=659, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=Sorafenib%20is%20an%20oral%20multi,10')
3. AnnotationURLCitation(end_index=938, start_index=782, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC')
4. AnnotationURLCitation(end_index=1217, start_index=1063, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=Primary%20liver%20cancer%20is%20a,such%20as%20epigenetic%20regulation')
5. AnnotationURLCitation(end_index=1552, start_index=1396, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC')
6. AnnotationURLCitation(end_index=1727, start_index=1553, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no')
7. AnnotationURLCitation(end_index=2449, start_index=2291, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=and%20reduced%20apoptosis%20,the%20malignant%20transformation%20of%20cells')
8. AnnotationURLCitation(end_index=2674, start_index=2510, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=aberration%20in%20EGFR%20pathways%20is,the%20effectiveness%20of%20cetuximab%20in')
9. AnnotationURLCitation(end_index=2891, start_index=2756, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=malignancies,cetuximab%20in%20patients%20with%20BCC')
10. AnnotationURLCitation(end_index=3327, start_index=3163, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=aberration%20in%20EGFR%20pathways%20is,the%20effectiveness%20of%20cetuximab%20in')
11. AnnotationURLCitation(end_index=3837, start_index=3697, title='Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20720388/#:~:text=The%20multikinase%20inhibitor%20sorafenib%20is,BCC%29%20while')
12. AnnotationURLCitation(end_index=4470, start_index=4309, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Cetuximab%20is%20a%20chimeric%20human%2Fmurine,There%20are%20reported%20cases')
13. AnnotationURLCitation(end_index=5080, start_index=4946, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Platinum,which%20were%20treated%20with%20cetuximab')
14. AnnotationURLCitation(end_index=5352, start_index=5194, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Results%3A%20Three%20of%20the%20four,and%20dose%20reduction%20in%20another')
15. AnnotationURLCitation(end_index=5707, start_index=5546, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=aberration%20in%20EGFR%20pathways%20is,cetuximab%20in%20patients%20with%20BCC')
16. AnnotationURLCitation(end_index=5966, start_index=5810, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=University%20School%20of%20Medicine%20%28SIU,Medical%20Oncology%20clinic')
17. AnnotationURLCitation(end_index=6732, start_index=6576, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC')
18. AnnotationURLCitation(end_index=7011, start_index=6855, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC')
19. AnnotationURLCitation(end_index=7433, start_index=7262, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Background%3A%20Epidermal%20growth%20factor%20receptor,in%20patients%20with%20advanced%20HCC')
20. AnnotationURLCitation(end_index=8832, start_index=8692, title='Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20720388/#:~:text=The%20multikinase%20inhibitor%20sorafenib%20is,BCC%29%20while')
21. AnnotationURLCitation(end_index=9584, start_index=9430, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=and%20reduced%20apoptosis%20,the%20effectiveness%20of%20cetuximab%20in')
22. AnnotationURLCitation(end_index=10038, start_index=9904, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Platinum,which%20were%20treated%20with%20cetuximab')
23. AnnotationURLCitation(end_index=10203, start_index=10039, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Among%20the%20four%20patients%20with,disease%20remission%20had%20been%20attained')
24. AnnotationURLCitation(end_index=10452, start_index=10288, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Among%20the%20four%20patients%20with,disease%20remission%20had%20been%20attained')
25. AnnotationURLCitation(end_index=10929, start_index=10768, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=aberration%20in%20EGFR%20pathways%20is,cetuximab%20in%20patients%20with%20BCC')
26. AnnotationURLCitation(end_index=11704, start_index=11533, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Background%3A%20Epidermal%20growth%20factor%20receptor,in%20patients%20with%20advanced%20HCC')
27. AnnotationURLCitation(end_index=11976, start_index=11805, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Background%3A%20Epidermal%20growth%20factor%20receptor,in%20patients%20with%20advanced%20HCC')
28. AnnotationURLCitation(end_index=12106, start_index=11977, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Results%3A%20Thirty%20patients%20were%20enrolled,3')
29. AnnotationURLCitation(end_index=12394, start_index=12265, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Results%3A%20Thirty%20patients%20were%20enrolled,3')
30. AnnotationURLCitation(end_index=12704, start_index=12575, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Results%3A%20Thirty%20patients%20were%20enrolled,3')
31. AnnotationURLCitation(end_index=12979, start_index=12805, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Conclusions%3A%20Although%20cetuximab%20could%20be,mild%20to%20moderate%20hepatic%20dysfunction')
32. AnnotationURLCitation(end_index=15259, start_index=15103, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC')
33. AnnotationURLCitation(end_index=15893, start_index=15737, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC')
34. AnnotationURLCitation(end_index=16237, start_index=16080, title='Sorafenib for the treatment of unresectable hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=Raf%20kinases%20and%20vascular%20endothelial,a%20RCT%20with%20a%20similar')
35. AnnotationURLCitation(end_index=16386, start_index=16238, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=match%20at%20L682%20pathways,many%20trials%20that%20failed%20to')
36. AnnotationURLCitation(end_index=16700, start_index=16543, title='Sorafenib for the treatment of unresectable hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=Raf%20kinases%20and%20vascular%20endothelial,a%20RCT%20with%20a%20similar')
37. AnnotationURLCitation(end_index=17137, start_index=16952, title='Sorafenib for the treatment of unresectable hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=angiogenesis%20effects%20in%20cancers%2C%20including,diarrhea%2C%20fatigue%2C%20and%20skin%20toxicity')
38. AnnotationURLCitation(end_index=17300, start_index=17138, title='Sorafenib for the treatment of unresectable hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=signal%20transduction%20pathways%20control%20the,7%3B%20Chang%20et%20al%202007')
39. AnnotationURLCitation(end_index=18046, start_index=17908, title='Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19496710/#:~:text=characteristics,prolonging%20median%20survival%20and%20time')
40. AnnotationURLCitation(end_index=18221, start_index=18047, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no')
41. AnnotationURLCitation(end_index=18485, start_index=18347, title='Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19496710/#:~:text=characteristics,prolonging%20median%20survival%20and%20time')
42. AnnotationURLCitation(end_index=18718, start_index=18580, title='Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19496710/#:~:text=characteristics,prolonging%20median%20survival%20and%20time')
43. AnnotationURLCitation(end_index=18959, start_index=18838, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=response%20with%20sorafenib,68%20and')
44. AnnotationURLCitation(end_index=19315, start_index=19154, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=difference%20in%20sorafenib%20and%20placebo%2C,ORR%29%20were%20disappointing')
45. AnnotationURLCitation(end_index=19730, start_index=19574, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC')
46. AnnotationURLCitation(end_index=19907, start_index=19731, title='Sorafenib for the treatment of unresectable hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=receptor%20tyrosine%20kinases%20associated%20with,agent%20for%20systemic%20chemotherapy%20in')
47. AnnotationURLCitation(end_index=20343, start_index=20190, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=match%20at%20L727%20In%20the,MKI%2C%20to%20the%20treatment%20arsenal')
48. AnnotationURLCitation(end_index=20639, start_index=20486, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=match%20at%20L727%20In%20the,MKI%2C%20to%20the%20treatment%20arsenal')
49. AnnotationURLCitation(end_index=21072, start_index=20913, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=In%20the%20ten%20years%20following,MKI%2C%20to%20the%20treatment%20arsenal')
50. AnnotationURLCitation(end_index=21206, start_index=21073, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=superiority,in%20the%20lenvatinib%20arm%20showed')
51. AnnotationURLCitation(end_index=21635, start_index=21497, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=bevacizumab%20vs.%20sorafenib%20%20,19.2%20vs.%2013.4')
52. AnnotationURLCitation(end_index=21903, start_index=21765, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=bevacizumab%20vs.%20sorafenib%20%20,19.2%20vs.%2013.4')
53. AnnotationURLCitation(end_index=22450, start_index=22287, title='SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023) | Clinical and Translational Oncology', type='url_citation', url='https://link.springer.com/article/10.1007/s12094-024-03568-4#:~:text=Some%20patients%20with%20advanced%20HCC,could%20still%20be%20considered')
54. AnnotationURLCitation(end_index=22937, start_index=22763, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=promote%20cell%20apoptosis%2C%20and%20inhibit,as%20targeting%20epigenetic%20pathways%20or')
55. AnnotationURLCitation(end_index=23072, start_index=22938, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=,future%20research%20and%20clinical%20application')
56. AnnotationURLCitation(end_index=23508, start_index=23346, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=urgent%20problem%20to%20be%20solved,provide%20suggestions%20for%20future%20in')
57. AnnotationURLCitation(end_index=23702, start_index=23509, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=programmed%20cell%20death%2C%20metabolic%20reprogramming%2C,depth%20research%20and%20clinical%20applications')
58. AnnotationURLCitation(end_index=24507, start_index=24351, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC')
59. AnnotationURLCitation(end_index=24900, start_index=24739, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=Sorafenib%20was%20shown%20to%20have,HFS%29%2C%20alopecia%2C%20and%20anorexia')
60. AnnotationURLCitation(end_index=25071, start_index=24901, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=was%20different,significant%20hypertension%2C%20proteinuria%2C%20and%20hypothyroidism')
61. AnnotationURLCitation(end_index=26103, start_index=25947, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=HCC%20treatment%20since%20the%20FDA,VEGF%2C%20are%20critical%20in%20HCC')
62. AnnotationURLCitation(end_index=26424, start_index=26250, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no')
63. AnnotationURLCitation(end_index=26546, start_index=26425, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=response%20with%20sorafenib,68%20and')
64. AnnotationURLCitation(end_index=28178, start_index=28004, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Conclusions%3A%20Although%20cetuximab%20could%20be,mild%20to%20moderate%20hepatic%20dysfunction')
65. AnnotationURLCitation(end_index=28539, start_index=28354, title='Sorafenib for the treatment of unresectable hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=angiogenesis%20effects%20in%20cancers%2C%20including,diarrhea%2C%20fatigue%2C%20and%20skin%20toxicity')
66. AnnotationURLCitation(end_index=28688, start_index=28540, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=match%20at%20L682%20pathways,many%20trials%20that%20failed%20to')
67. AnnotationURLCitation(end_index=29041, start_index=28879, title='Sorafenib for the treatment of unresectable hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=signal%20transduction%20pathways%20control%20the,7%3B%20Chang%20et%20al%202007')
68. AnnotationURLCitation(end_index=29312, start_index=29138, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no')
69. AnnotationURLCitation(end_index=29618, start_index=29456, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=urgent%20problem%20to%20be%20solved,provide%20suggestions%20for%20future%20in')
70. AnnotationURLCitation(end_index=29741, start_index=29619, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=Sorafenib%20is%20an%20oral%20multi,10')
71. AnnotationURLCitation(end_index=31009, start_index=30835, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=The%20OS%20primary%20outcome%20demonstrated,progression%20primary%20outcome%20showed%20no')
72. AnnotationURLCitation(end_index=31131, start_index=31010, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=response%20with%20sorafenib,68%20and')
73. AnnotationURLCitation(end_index=31367, start_index=31246, title='Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10854554/#:~:text=response%20with%20sorafenib,68%20and')
74. AnnotationURLCitation(end_index=31627, start_index=31470, title='Sorafenib for the treatment of unresectable hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=Raf%20kinases%20and%20vascular%20endothelial,a%20RCT%20with%20a%20similar')
75. AnnotationURLCitation(end_index=31804, start_index=31628, title='Sorafenib for the treatment of unresectable hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2727884/#:~:text=receptor%20tyrosine%20kinases%20associated%20with,agent%20for%20systemic%20chemotherapy%20in')
76. AnnotationURLCitation(end_index=32055, start_index=31921, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Platinum,which%20were%20treated%20with%20cetuximab')
77. AnnotationURLCitation(end_index=32214, start_index=32056, title='Cetuximab in Refractory Skin Cancer Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3376776/#:~:text=Results%3A%20Three%20of%20the%20four,and%20dose%20reduction%20in%20another')
78. AnnotationURLCitation(end_index=32456, start_index=32327, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Results%3A%20Thirty%20patients%20were%20enrolled,3')
79. AnnotationURLCitation(end_index=32631, start_index=32457, title='Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17583545/#:~:text=Conclusions%3A%20Although%20cetuximab%20could%20be,mild%20to%20moderate%20hepatic%20dysfunction')
80. AnnotationURLCitation(end_index=32883, start_index=32743, title='Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/20720388/#:~:text=The%20multikinase%20inhibitor%20sorafenib%20is,BCC%29%20while')
81. AnnotationURLCitation(end_index=33181, start_index=33007, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=promote%20cell%20apoptosis%2C%20and%20inhibit,as%20targeting%20epigenetic%20pathways%20or')
82. AnnotationURLCitation(end_index=33304, start_index=33182, title='Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12175829/#:~:text=Sorafenib%20is%20an%20oral%20multi,10')
83. AnnotationURLCitation(end_index=33593, start_index=33430, title='SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023) | Clinical and Translational Oncology', type='url_citation', url='https://link.springer.com/article/10.1007/s12094-024-03568-4#:~:text=Some%20patients%20with%20advanced%20HCC,could%20still%20be%20considered')